Condition: Metastatic Tumor · Advanced Solid Tumor · Renal Cell Carcinoma · Sponsor: Weijia Fang, MD
This is a phase I clinical study to evaluate the safety and tolerability of CAR-T in patients with CD70-positive advanced/metastatic solid tumors, and to obtain the maximum tolerated dose of CAR-T and phase II Recommended dose.
This description comes directly from the study's public registry record.
Weijia Fang, M.D · 13758211655 · weijiafang@zju.edu.cn
Always discuss trial participation with your own doctor first.
| First affiliated hospital, Zhejiang University | Hangzhou, Zhejiang, China | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05518253